Immuron Limited (ASX:IMC): FY26 Sales, Oral Antibody Programs and Commercial Priorities

Aditi Sarkar

12 October 2026 05:44 PM AEDT

Immuron Limited (ASX:IMC): FY26 Sales, Oral Antibody Programs and Commercial Priorities

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 global sales Revenue reached $7.7m, representing growth of 6%.
Australian and US sales contributed to the company’s annual commercial performance.
Travelan remains a central product within Immuron’s gastrointestinal portfolio.
IMM-529 and other clinical programs sit alongside its commercial operations.
The company outlined Cash Management and product expansion priorities for FY27.

Immuron Limited (ASX:IMC) develops and commercialises orally delivered polyclonal antibodies derived from hyperimmune bovine colostrum for gastrointestinal disease prevention and treatment. Its operations combine the Travelan product Business with clinical development programs, including IMM-529. FY26 disclosures provide an updated picture of sales performance, development activities and financial resources as the company approaches FY27.

FY26 Revenue and Financial Position

Immuron Limited (ASX:IMC) reported global FY26 sales revenue of $7.7m, an increase of 6%. Australian sales revenue was $5.8m, up 10%, while United States revenue reached $1.8m, up 7% in the company’s reporting presentation. The company also reported a Gross Profit Margin of 64.5%, a decline of 0.9 percentage points.

The FY26 presentation recorded a net loss of $3.8m, an improvement of $1.4m, and cash of $9.0m at 30 June 2026. These figures place commercial sales growth alongside the company’s continuing expenditure on product distribution, research and development. The results presentation described the figures as preliminary and subject to audit review.

Travelan Distribution and Product Portfolio

Travelan is an oral antibody-based product associated with reducing the risk of travellers’ diarrhoea. For ASX:IMC, its Australian and overseas distribution channels are important to assessing the development of recurring product sales. The company’s FY26 disclosures identified four consecutive quarters of Travelan sales growth compared with corresponding prior-year quarters.

Immuron also markets ProIBS in Australia for symptoms associated with irritable bowel syndrome. This expands the company’s gastrointestinal offering beyond travel-related products. However, retail distribution, consumer Demand and country-specific product rules can influence the pace of commercial expansion for ASX:IMC.

Clinical Development and Regulatory Milestones

Alongside marketed products, Immuron Limited (ASX:IMC) is developing IMM-529 for recurrent Clostridioides difficile infection. During FY26, the company reported US Food and Drug Administration clearance of its investigational new drug application, permitting clinical development under the applicable regulatory framework. This clearance does not constitute Marketing approval or establish clinical effectiveness.

The company also reported completion of an 851-participant Travelan study and a new US Department of Defense research subaward. These activities are distinct from commercial revenue: the ultimate significance of clinical research depends on reported outcomes, subsequent regulatory decisions and the resources needed to progress development.

FY27 Priorities and Business Risks

In its FY26 results presentation, ASX:IMC identified continued Travelan sales growth, portfolio expansion, broader geographic reach and an IMM-529 partnering update among its FY27 priorities. Management also indicated its expectation that existing cash could support operations through FY27–FY28; this remains company guidance rather than an assured outcome.

Commercial execution remains exposed to pharmacy and distributor relationships, product competition and varying healthcare regulation. Clinical initiatives face study, regulatory and funding uncertainty. The company’s financial position therefore needs to be considered together with its commercial margins and expenditure commitments.

Key Insights

Immuron Limited (ASX:IMC) combines an established gastrointestinal product business with earlier-stage antibody development. FY26 results showed higher sales and a narrower reported net loss, while IMM-529 and related programs remain subject to clinical and regulatory progress. The distinction between documented commercial activity and unproven future clinical outcomes is central to understanding the company’s operating profile.

FAQs

Q:What does Immuron Limited produce?

A:It develops oral antibody products for gastrointestinal conditions and sells products including Travelan.

Q:What was Immuron’s FY26 global sales revenue?

A:The company reported $7.7m in global sales revenue, up 6%.

Q:What is IMM-529?

A:IMM-529 is a clinical development candidate being investigated for recurrent C. difficile infection.

Q:Did Immuron report a profit in FY26?

A:No. Its preliminary FY26 presentation reported a $3.8m net loss.

Q:What are the key operating considerations for FY27?

A:Commercial distribution, product performance, clinical development spending and available cash remain relevant.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.